<DOC>
	<DOCNO>NCT00892840</DOCNO>
	<brief_summary>The purpose study determine safety tolerability BMS-820836 multiple dos</brief_summary>
	<brief_title>Multiple-Ascending Dose Study</brief_title>
	<detailed_description />
	<criteria>Panels 16 : Healthy Male Subjects Panel 7 : Females Ages 21 55 , inclusive Body Mass Index ( BMI ) 18 32 kg/m2 , inclusive Healthy subject determine clinically significant deviation normal medical history , physical examination , ECGs , clinical laboratory determination Any major surgery within 4 week study drug administration History cholecystectomy History glaucoma confirm intraocular pressure indicative glaucoma screening . ( Normal IOP &lt; 21 mmHg ) Confirmed QTc ( Fridericia ) value ≥ 450 msec Confirmed QT ≥ 500 msec Confirmed PR ≥ 210 msec Confirmed QRS ≥ 120 msec Confirmed rest supine systolic blood pressure &gt; 140 mmHg Confirmed rest supine diastolic blood pressure &gt; 90 mmHg Confirmed rest heart rate &lt; 45 bpm &gt; 100 bpm Orthostatic vital sign change ( ie. , decrease systolic blood pressure supine stand &gt; 40 mmHg increase heart rate supine stand &gt; 20 bpm ) symptoms orthostasis History peppermint allergy Exposure investigational drug placebo within 12 week study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>